Project Grant R01AI191753
- The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $238,500 project grant to the University of California, San Diego (UC San Diego) to develop a novel electrochemical lateral flow assay (ELFA) for the point-of-need diagnosis of tuberculosis (TB). The objective is to create a highly sensitive and specific blood or urine test that can accurately distinguish active TB disease from...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,760,584 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the Regents of the University of California, San Francisco (UCSF) for the "RAPID RESEARCH FOR DIAGNOSTICS DEVELOPMENT IN TB NETWORK: EPISODE 2 (R2D2 TB NETWORK II)" project. The goal of this project is to address the critical unmet need for better tuberculosis (TB) diagnostics in high-burden...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $536,148 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine to conduct research on integrating point-of-care urine isoniazid testing into routine tuberculosis (TB) care in India. The research aims to facilitate early and accurate identification of TB patients who are at risk of poor outcomes, including death and disease recurrence, due to...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
- This Project Grant award of $856,202 was provided by the National Institute of Allergy and Infectious Diseases (NIAID), which oversees the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award will fund a 5-year study led by researchers at the University of California, San Francisco (UCSF) to investigate the role of IL-10 and IFN signaling in controlling the HIV reservoir and achieving functional HIV cure. The project aims to determine if enhancing IL-10 and...
- This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $776,341 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois on September 16, 2025. The purpose of this grant is to develop a microfluidic cartridge, molecular biology method, biosensor, and detection instrument that can simultaneously detect HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) viral loads from a minimal 100 μL whole blood sample. This...
- The University of California, San Francisco (UCSF) was awarded a $675,962 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the grant is to characterize the interaction between human and vector behaviors in order to enhance the impact of malaria control interventions in Uganda. The project will integrate rigorous human behavioral and entomological monitoring data to elucidate...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $256,504 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant will fund the planning of an open-label, randomized, controlled Phase 2C clinical trial to evaluate novel 4-month treatment regimens for isoniazid-monoresistant tuberculosis (IMR-TB) compared to the current 6-month standard of care. The trial...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $368,750 Project Grant to the Veterans Medical Research Foundation of San Diego through the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The project aims to determine the mechanisms by which the short isoform of the BST2 protein, which has broad antiviral activity, is antagonized by HIV-1 and HIV-2. This research seeks to understand how HIV evades this key cellular defense and the...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $694,883 Project Grant to the Regents of the University of California, San Francisco (UCSF). The grant, awarded on September 15, 2025, supports research to evaluate a point-of-care urine tenofovir (TFV) assay developed by UCSF researchers as a tool to triage HIV drug resistance testing in South Africa. The project aims to compare the urine TFV assay to other adherence metrics in predicting dolutegravir (DTG) resistance among people living with HIV who have experienced virologic failure on the TDF-lamivudine-dolutegravir (TLD) first-line therapy. The research will assess the ability of the urine TFV assay to cost-effectively identify individuals who should undergo HIV drug resistance testing in resource-limited settings.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $256.7k | 9/15/25 | ||
| Not listed | $438.2k | 9/12/25 |